All In Biotech

BLA 205747 · Eli Lilly and CO

Humalog Kwikpen

Insulin Lispro Recombinant · Subcutaneous · Insulin Analog

Last checked: Nov 20, 2026Latest source record: May 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

May 26, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

15

0 Phase 3, 0 recruiting

FAERS reports

127,036

60,392 serious, 5,735 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 16, 2026.

HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

Mechanism: Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 26, 2015 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
  • HUMALOG KWIKPEN · INSULIN LISPRO RECOMBINANT 200 UNITS/ML · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Lispro Recombinant" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased35,855
  • incorrect dose administered8,446
  • blood glucose decreased8,255
  • drug ineffective7,655
  • visual impairment5,017
  • nausea4,777
  • malaise3,727
  • fatigue3,668
  • hypoglycaemia3,662
  • fall3,334
  • drug dose omission3,313
  • diarrhoea3,165

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,188
20051,265
20061,680
20071,554
20081,463
20091,792
20101,841
20112,034
20122,106
20131,712
20144,564
201524,743
20168,420
20178,456
20188,846
20198,869
20209,074
20217,658
20226,679
20235,810
20245,439
20257,926
20263,917

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.